Synthesis, Activity, and Molecular Modeling Studies of Novel Human Aldose Reductase Inhibitors Based on a Marine Natural Product

Journal of Medicinal Chemistry

Volumn 46, Issue 24, 2003, Pages 5208-5221

  De La Fuente, Jesús Ángel ^a   Manzanaro, Sonia ^a   Martín, María Jesús ^b   De Quesada, Teresa G ^b   Reymundo, Isabel ^b   Luengo, Santos M ^c   Gago, Federico ^c  

^a Instituto Biomar SA   (Spain)

^b PHARMAMAR S A   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',4,4'5,5' HEXACHLORO 2,2' DIHYDROXYDIPHENYL ETHER; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; BROMINE; BROMOBENZENE; CHLOROBENZENE; DIPHENYL ETHER DERIVATIVE; FLUOROBENZENE; IDITOL DEHYDROGENASE; NATURAL PRODUCT; POLYBROMINATED DIPHENYL ETHER; POLYOL; SORBINIL; SORBITOL; TOLRESTAT; UNCLASSIFIED DRUG; ZENARESTAT; ZOPOLRESTAT;

ARTICLE; BLINDNESS; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MOLECULAR DYNAMICS; MOLECULAR MODEL; RETINA CELL; SPONGE (PORIFERA); STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

ALDEHYDE REDUCTASE; ANIMALS; BINDING SITES; BIOLOGICAL FACTORS; ELECTROSTATICS; HUMANS; MODELS, MOLECULAR; POLYBROMINATED BIPHENYLS; PORIFERA; RETINA; SORBITOL; THERMODYNAMICS;

EID: 0242607620     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030957n     Document Type: Article

References (61)

1. Brownlee, M. Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature 2001, 414, 813-820.
2. Gabbay, K. H. The Sorbitol Pathway and the Complications of Diabetes. N. Engl. J. Med. 1973, 288, 831-836.
3. Kador, P. F. The Role of Aldose Reductase in the Development of Diabetic Complications. Med. Res. Rev. 1988, 8, 325-352.
4. Tomlinson, D. R.; Stevens, E. J.; Diemel, L. Aldose Reductase Inhibitors and Their Potential for the Treatment of Diabetic Complications. Trends Pharmcol. Sci. 1994, 15, 293-297.
5. Crabbe, M. J. C.; Goode, D. Aldose Reductase: a Window to the Treatment of Diabetic Complications? Prog. Retin. Eye Res. 1998, 17, 313-383.
6. Yabe-Nishimura, C. Aldose Reductase in Glucose Toxicity: a Potential Target for the Prevention of Diabetic Complications. Pharmacol. Rev. 1998, 50, 21-33.
7. Carper, D. A.; Wistow, G.; Nishimura, C.; Graham, C.; Watanabe, K.; Fujii, Y.; Hayashi, H.; Hayaishi, O. A Superfamily of NADPH-Dependent Reductases in Eukaryotes and Prokaryotes. Exp. Eye Res. 1989, 49, 377-388.
8. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes Complications and Their Potential Prevention: Aldose Reductase Inhibition and Other Approaches. Med. Res. Rev. 1999, 19, 3-23.
9. Costantino, L.; Rastelli, G.; Cignarella, G.; Vianello, P.; Barlocco, D. New Aldose Reductase Inhibitors as Potential Agents for the Prevention of Long-term Diabetic Complications. Exp. Opin. Ther. Pat. 1997, 7, 843-858.
10. Sarges, R.; Oates, P. J. Aldose Reductase Inhibitors: Recent Developments. Prog. Drug Res. 1993, 40, 99-161.
11. De la Fuente, J. A.; Manzanaro, S. Aldose Reductase Inhibitors from Natural Sources. Nat. Prod. Rep. 2003, 20, 243-251.
12. Rondeau, J.-M.; Tete-Favier, F.; Podjarny, A.; Reymann, J. M.; Barth, P. ; Biellmann, J. F.; Moras, D. Novel NADPH-binding Domain Revealed by the Crystal Structure of Aldose Reductase. Nature (London) 1992, 355, 469-472.
13. Urzhumtsev, A.; Tete-Favier, F.; Mitschler, A.; Barbanton, J.; Parth, P. ; Urzhumtseva, L.; Biellmann, J.-F.; Podjarny, A. D.; Moras, D. A 'Specificity' Pocket Inferred from the Crystal Structures of the Complexes of Aldose Reductase with Pharmaceutically Important Inhibitors Tolrestat and Sorbinil. Structure 1997, 5, 601-612.
14. Wilson, D. K.; Bohren, K. M.; Gabbay, K. H.; Quiocho, F. A. An Unlikely Sugar Substrate in the 1.65 A Structure of the Human Aldose Reductase Holoenzyme Implicated in Diabetic Complications. Science 1992, 257, 81-84.
15. Wilson, D. K.; Tarle, I.; Petrash, J. M.; Quiocho, F. A. Refined 1.8 Å Structure of Human Aldose Reductase Complexed with the Potent Inhibitor Zopolrestat. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9847-9851.
16. Warren, J. C.; Murdock, G. L.; Ma, Y.; Goodman, S. R.; Zimmer, W. E. Molecular Cloning of Testicular 20 Alpha-Hydroxysteroid Dehydrogenase: Identity with Aldose Reductase. Biochemistry 1993, 32, 1401-1406.
17. Várnai, P.; Warshel, A. Computer Simulation Studies of the Catalytic Mechanism of Human Aldose Reductase. J. Am. Chem. Soc. 2000, 122, 3849-3860.
18. Sugiyama, K.; Chen, Z.; Lee, Y. S.; Kador, P. F. Isolation of a Non-Covalent Aldose Reductase-Nucleotide-Inhibitor Complex. Biochem. Pharmacol. 2000, 59, 329-336.
19. Bohren, K. M.; Grimshaw, C. E. The Sorbinil Trap: a Predicted Dead-end Complex Confirms the Mechanism of Aldose Reductase Inhibition. Biochemistry 2000, 39, 9967-9974.
20. Rastelli, G.; Antolini, L.; Benvenuti, S.; Costantino, L. Structural Bases for the Inhibition of Aldose Reductase by Phenolic Compounds. Bioorg. Med. Chem. 2000, 8, 1151-1158.
21. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Vinson, J. A.; Bose, P.; Iannone, A.; Staffieri, M. G.; Antolini, L.; Del Corso, A.; Mura, U.; Albasini, A. 1-Benzopyran-4-one Antioxidants as Aldose Reductase Inhibitors. J. Med. Chem. 1999, 42, 1881-1893.
22. Pfeifer, M. A.; Schumer, M. P.; Gelber, D. A. Aldose Reductase Inhibitors: the End of an Era or the Need for Different Trial Designs? Diabetes 1997, 46 Suppl. 2, S82-89.
23. 1H Coupling Constants. Tetrahedron 1981, 37, 2341-2349.
24. Masashi, N.; Misako, I.; Yoshihiro, H.; Mamoru, E. Aldose Reductase Inhibitor from Palauan Sponges. Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 1986, 28, 200-207.
25. Fu, X.; Schmitz, F. J.; Govindan, M.; Abbas, S. A.; Hanson, K. M.; Horton, P. A.; Crews, P.; Laney, M.; Schatzman, R. C. Enzyme Inhibitors: New and Known Polybrominated Phenols and Diphenyl Ethers from Four Indo-Pacific Dysidea Sponges. J. Nat. Prod. 1995, 58, 1384-1391.
26. Carté, B.; Faulkner, J. Polybrominated Diphenyl Ethers from Dysidea herbacea, Dysidea chlorea and Phyllospongia foliascens. Tetrahedron 1981, 37, 2335-2339.
27. 2 Inhibitory Activity of Thielocin B3 Derivatives. J. Med. Chem. 1996, 39, 5183-5191.
28. Murakami, Y.; Yokoyama, Y.; Sasakura, C.; Tamagawa, M. An Efficient Synthesis of 1,1′-Disubstituted Hydrazines. Chem. Pharm. Bull. 1983, 31, 423-428.
29. Nakai, N.; Fujii, Y.; Kobashi, K.; Nomura, K. Aldose Reductase Inhibitors: Flavonoids, Alkaloids, Acetophenones, Benzophenones, and Spirohydantoins of Chroman. Arch. Biochem. Biophys. 1985, 239, 491-496.
30. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
31. Kmunicek, J.; Luengo, S.; Gago, F.; Ramirez Ortiz, A.; Wade, R.; Damborsky, J. Comparative Binding Energy (COMBINE) Analysis of the Substrate Specificity of Haloalkane Dehalogenase from Xanthobacter autotrophicus GJ10. Biochemistry 2001, 40, 8905-8917.
32. Kinoshita, T.; Miyake, H.; Fujii, T.; Takakura, S.; Goto, T. The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat. Acta Crystallogr. D Biol. Crystallogr. 2002, 58, 622-626.
33. Hansch, C.; Leo, A. In Substituent Constants for Correlation Analysis in Chemistry and Biology; John Wiley: New York, 1979.
34. Lobatón, E.; Rodriguez-Barrios, F.; Gago, F.; Pé rez-Pérez, M. J.; De Clercq, E.; Balzarini, J.; Camarasa, M. J.; Velázquez, S. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J. Med. Chem. 2002, 45, 3934-3945.
35. Kime, D. E.; Norymberski, J. K. Synthesis of Fully Aromatic Cyclic Polyethers. J. Chem. Soc., Perkin Trans. 1 1977, 1048-1052.
36. Deng, G.; James, T. D.; Shinkai, S. Allosteric Interactions of Metal Ions with Saccharides in a Crowned Diboronic Acid. J. Am. Chem. Soc. 1994, 116, 4567-4572.
37. McOmie, J. F. W.; West, D. E. Organic Syntheses; Wiley: New York, 1973; Collect. Vol. V, p 412.
38. Rao, A. V. R.; Gurjar, M. K.; Kaiwar, V.; Khare, V. B. An Expedient Approach to the Diphenyl Ether Cross-linked Amino Acids of Glycopeptide Antibiotics. Tetrahedron Lett. 1993, 34, 1661-1664.
39. Ungnade, H. E.; Zilch, K. T. Phenoxyquinones II. The Diphenoxyquinones. J. Org. Chem. 1951, 16, 64-69.
40. Allard, A.-S.; Remberger, M.; Neilson, A. H. Bacterial O-Methylation of Halogen-Substituted Phenols. Appl. Environ. Microbiol. 1987, 53, 839-845.
41. Scarborough, H. A.; Sweeten, J. L, Substitution Products of 2′-Nitro- and 2′:4′-Dinitro-2-methoxy-diphenyl Ethers. J. Chem. Soc. 1934, 867-869.
42. Cullinane, N. M.; Davey, H. G.; Padfield, H. J. H. Investigations in the Diphenylene Oxide Series. Part IV. J. Chem. Soc. 1934, 716-719.
43. Olmsted, M. P.; Craig, P, N.; Lafferty, J. J.; Pavloff, A. M.; Zirkle, C. L. Analogues of Phenothiazines. II. Phenoxazine and Phenoselenazine Analogues of Phenothiazine Drugs. J. Org. Chem. 1961, 26, 1901-1907.
44. Glombitza, K. W.; Woelwer-Rieck, U. Antibiotics from Algae. 38. Base-catalyzed Reactions of Multiple Hydroxylated Diphenyl Ethers. Liebigs Annalen der Chemie 1988, 3, 261-265.
45. Nishimura, C.; Yamaoka, T.; Mizutani, M.; Yamashita, K.; Akera, T.; Tanimoto, T. Purification and Characterization of the Recombinant Human Aldose Reductase Expressed in Baculovirus System. Biochim. Biophys. Acta. 1991, 1078, 171-178.
46. Nishimura, C.; Matsuura, Y.; Kokai, Y.; Akera, T.; Carper, D.; Morjana, N.; Lyons, C.; Flynn, T. G. Cloning and Expression of Human Aldose Reductase. J. Biol. Chem. 1990, 265, 9788-9792.
47. Rink, H.; Baumstark-Khan, C. Cell Culture Methods. In Manual of Oculotoxicity; Hockwin, O., Green, K., Rubin, L. F., Eds.; Gustav Fischer Verlag: Stuttgart, Germany, 1992; pp 389-401.
48. Yaginuma, S.; Asahi, A.; Takada, M.; Hayashi, M.; Tsujino, M.; Mizuno, K. Aldostatin, a New Aldose Reductase Inhibitor. In Novel Microbial Products for Medicine and Agriculture; Demain, A. L., Somkuti, G. A., Hunter-Cevera, J. C., Rossmore, H. W., Eds.; Society for Industrial Microbiology; Elsevier Science Ltd: New York, 1989; pp 127-133.
49. Gaussian 94, Revision E.1, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B. ; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Cioslowski, J.; Stefanov, B. B.; Nanayakkara, A.; Challacombe, M.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J. ; Binkley, J. S.; Defrees, D. J.; Baker, J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C. and Pople, J. A., Gaussian, Inc., Pittsburgh, PA, 1995.
50. Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges: the RESP Model. J. Phys. Chem. 1993, 97, 10269-10280.
51. Lide, D. R. CRC Handbook of Chemistry and Physics; CRC Press: Boca Raton, FL, 1997.
52. Jeffrey, G. A.; Ruble, J. R.; McMullan, R. K.; Pople, J. A. The Crystal Structure of Deuterated Benzene. Proc. R. Soc. London A 1987, 414, 47-57.
53. Fox, T.; Kollman, P. A, Application of the RESP Methodology in the Parametrization of Organic Solvents. J. Phys. Chem. B. 1998, 102, 8070-8079.
54. Insight II, version 98.0, 1998. Molecular Simulations Inc. 9685 Scranton Road, San Diego, CA 92121-2777.
55. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarekian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
56. Morris, G. M.; Goodsell, D. S.; Huey, R.; Hart, W. E.; Halliday, S.; Belew, R.; Olson, A. J. AutoDock: Automated Docking of Flexible Ligands to Receptors, Version 3,0; The Scripps Research Institute: La Jolla, CA, 1999.
57. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of Simple Potential Functions for Simulating Liquid Water. J. Chem. Phys. 1983, 79, 926-935.
58. Gilson, M. K.; Sharp, K. A.; Honig, B. H. Calculating the Electrostatic Potential of Molecules in Solution: Method and Error Assessment. J. Comput. Chem. 1987, 9, 327-335.
59. Pérez, C.; Ortiz, A. R.; Pastor, M.; Gago, F. Comparative Binding Energy Analysis of HIV-1 Protease Inhibitors: Incorporation of Solvent Effects and Validation as a Powerful Tool in Receptor-Based Drug Design. J. Med. Chem. 1998, 41, 836-852.
60. Cuevas, C.; Pastor, M.; Pérez, C.; Gago, F. Comparative Binding Energy (COMBINE) Analysis of Human Neutrophil Elastase Inhibition by Pyridone-containing Trifluoromethylketones. Comb. Chem. High Throughput Screen, 2001, 4, 627-642.
61. Pearlmann, D. A. Determining the Contributions of Constraints in Free Energy Calculations: Development, Characterization, and Recommendations. J. Chem. Phys. 1993, 98, 8946-8957.